The key strength of CAR-T cell therapy is that specific tumour antigens can be targeted to direct an immunological response, independent of antigen-presenting cells (APCs), as well as the major histocompatibility complex system (MHC) [55]. The gene discussed is HLA-C; the disease is neoplasm.